Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

Noveome Biotherapeutics

Status and phase: Completed; Phase 1

Conditions: Cytokine Release Syndrome

Treatments: Biological: ST266

Study type: Interventional

Funder types: Industry

Identifiers

NCT04720378

ST266-CRS-101

Details and patient eligibility

About

The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.

Full description

This clinical trial will utilize a 3+3 enrollment design with sentinel approach.

Enrollment: 12 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males and non-pregnant/non-breastfeeding females age 18-70 years of age.
2. Laboratory confirmed SARS-CoV-2 infection determined by PCR or other commercial/public health assay (test results must be obtained within 7-days of the Screening Visit).
3. BMI between 18 and 39 inclusive, with a maximum weight of 150 kg (330lbs).
4. Asymptomatic or mildly symptomatic COVID-19 positive subject with a score of 1 or 2 on the WHO 7-point ordinal scale.
5. Subjects with pulse oximetry of > 94% on room air
6. Subjects have controlled blood pressure of < 160/100 mmHg or systolic BP > 90 mmHg (or 20 mmHg less than usual range, whichever is higher)
7. Subjects with pulse < 120 bpm
8. Willingness and ability to comply with study-related procedures and assessments.
9. If female, subjects must use an effective method of birth control or abstain from sexual relations with a male partner (unless has undergone tubal ligation or is 1 year postmenopausal) for their duration of study participation.
10. If male, subjects must use an effective method of birth control or abstain from sexual relations with a female partner (unless has undergone a vasectomy and it has been more than 6 months) for their duration of study participation.
11. Subject or subject's legal representative provides written consent prior to the initiation of any Screening or study specific procedures.

Exclusion criteria

1. Subjects requiring immediate admission to the hospital due to complications of COVID-19 infection.
2. Subject has an untreated active bacterial, fungal, viral or other infection not related to COVID-19 infection.
3. Subjects with chronic lung diseases of any etiology including idiopathic pulmonary fibrosis, Tuberculosis, COPD, persistent asthma, and pulmonary hypertension.
4. Subjects with a severe history of cardiac disease (such as congestive heart failure, coronary artery disease, cardiac arrhythmia)
5. Subjects with a history of neurological disorders (such as epilepsy, stroke, encephalopathy, Guillain-Barré syndrome)
6. Subjects with D-dimer > 2 ug/mL
7. Subjects with a history of coagulopathy or currently taking anti-coagulation medication
8. Subjects with PTT ≥ 100s or INR ≥ 2.75
9. Malignancy in the last 5 years (except successfully treated basal cell carcinoma).
10. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., eGFR < 30).
11. Subjects with a reactive or positive screening test result For Hepatitis A virus immunoglobulin M (HAV IgM), Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus Antibody (HCVAb) or Human Immunodeficiency Virus Antibody (HIVAb).
12. TBIL> 2×ULN, ALT > 3×ULN, AST> 3×ULN, or ALP> 3×ULN.
13. Neutrophils <1000/mm3, PLT<50×10^9/L, or HGB<8g/dL
14. Previous participation in any other interventional clinical trial for the treatment for COVID-19.
15. Subject actively participating in any other clinical study (with the exception of observational studies where there is no intervention with an investigational product or device)
16. Use of anti-cancer or immunomodulatory biological drug or kinase inhibitor (e.g., tocilizumab, sarilumab) or, JAK inhibitors (within 30 days of enrollment or five times the half-life [whichever is longer]).
17. Chronic glucocorticosteroid use equivalent to daily oral prednisone > 10 mg per day (10 mg oral prednisone every other day is allowed).
18. Live (live-attenuated) vaccines are not permitted within 2 weeks prior to enrollment or during the study treatment and safety follow-up periods, including the SARS-CoV-2 vaccine (with the exception of the Flu vaccine which is allowed at any time)
19. Subject is pregnant or breastfeeding or plans to become pregnant within 12 months.
20. Subjects with a history of alcohol or drug abuse, or the use of illicit drugs within the 12 months prior to Screening or use of medical marijuana within 1 month prior to Screening.
21. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

12 participants in 4 patient groups

Cohort 1

Experimental group

Description:

0.1 ml/kg IV ST266 once a day for 5 days

Treatment:

Biological: ST266

Cohort 2

Experimental group

Description:

0.25 ml/kg IV ST266 once a day for 5 days

Treatment:

Biological: ST266

Cohort 3

Experimental group

Description:

0.5 ml/kg IV ST266 once a day for 5 days

Treatment:

Biological: ST266

Cohort 4

Experimental group

Description:

1.0 ml/kg IV ST266 once a day for 5 days

Treatment:

Biological: ST266